您的购物车当前为空
Tegoprazan 是一种口服有效的、高选择性胃 H+/K+-ATP 酶 (H+/K+-ATPase) 抑制剂,能够控制胃酸分泌和运动,在体外检测的对猪、犬、人的 H+/K+-ATP 酶的 IC50为0.29-0.52 μM。

Tegoprazan 是一种口服有效的、高选择性胃 H+/K+-ATP 酶 (H+/K+-ATPase) 抑制剂,能够控制胃酸分泌和运动,在体外检测的对猪、犬、人的 H+/K+-ATP 酶的 IC50为0.29-0.52 μM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 497 | 现货 | |
| 5 mg | ¥ 1,230 | 现货 | |
| 10 mg | ¥ 1,880 | 现货 | |
| 25 mg | ¥ 3,150 | 现货 | |
| 50 mg | ¥ 4,130 | 现货 | |
| 100 mg | ¥ 5,880 | 待询 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,050 | 现货 |
Tegoprazan 相关产品
| 产品描述 | Tegoprazan is an orally active, highly selective gastric H+/K+-ATPase inhibitor that controls gastric acid secretion and motility, with an IC50 of 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPase in vitro. |
| 靶点活性 | H+, K+-ATPase:0.29-0.52 μM |
| 体外活性 | 方法:Tegoprazan (CJ-12420)(0,0.0005,0.001,0.005,0.01,0.05,0.1,0.5,1,10,100 和,1000 μg/mL,24小时)培养 BMM 细胞,探究其 对 BMM 细胞毒性和一氧化氮 (NO) 产生的影响。 |
| 体内活性 | 方法:Tegoprazan (CJ-12420)(3,10 mg/kg,口服,5天)治疗幽门结扎大鼠,观察其和埃索美拉唑对幽门结扎大鼠胃酸分泌的影响。 |
| 分子量 | 387.38 |
| 分子式 | C20H19F2N3O3 |
| CAS No. | 942195-55-3 |
| Smiles | CN(C)C(=O)c1cc(O[C@H]2CCOc3cc(F)cc(F)c23)c2[nH]c(C)nc2c1 |
| 密度 | 1.371 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 22.5 mg/mL (58.08 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.16 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容